Monday, October 05, 2020 8:58:28 AM
Icecure Medical Ltd ICUSF:OTC Pink - Current Information
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
PR Newswire
8:00 AM ET
IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that it has expanded its strategic partnership with Terumo Corporation (Tokyo: 4543) (TRUMY: OTC US), a leading Japanese medical devices company with a global footprint. The expanded partnership reflects the ongoing success of the initial agreement, which was signed in September 2019, and included distribution rights in Japan and Singapore. The new multi-million dollar agreement, which is expected to be finalized by the end of the year, will grant Terumo exclusive rights to distribute IceCure's products in Thailand for six years, with an option to extend the agreement for an additional six years.
Under the terms of a Letter of Intent (LOI), in exchange for granting exclusive distribution rights and knowledge-sharing for ProSense(TM) and its consumables for the initial six-year period of years, the agreement includes a payment of $450,000 that will be paid by Terumo in three instalments over two years. The first payment of $150,000, along with Terumo's first purchase order (PO) of approximately $329,000, will be due upon execution of the final agreement.
"Thailand, along with Japan and Singapore, are key geographies for IceCure in Southeast Asia, and with approximately 170,000 new cases of cancer every year, we believe patients will greatly benefit from IceCure's ProSense(TM) cryoablation system," commented Eyal Shamir, IceCure's CEO. "The extension of our existing strategic collaboration with Ter umo demonstrates its confidence in our technology and lays the foundation for continued global expansion as we seek to rapidly bring our minimally-invasive cryoablation treatment to help patients worldwide."
"This achievement is a continuation of our business strategy to collaborate with strategic distributors in order to accelerate commercialization of technology to offer healthcare facilities with alternative oncology solutions. Moreover, our ProSense(TM) minimally-invasive system eliminates the need to have the patient in the operating room, a significant advantage in today's healthcare environment as medical facilities are managing the COVID-19 pandemic to reduce risks of infectious pathogens and freeing up medical resources."
"We are delighted to expand and strengthen our collaboration with IceCure. As we continue to address key unmet medical needs, IceCures innovative ProSense(TM) cryoablation system provides a vital non-surgical alternative for cancer patients seeking treatment in Thailand. We look forward to working together and exploring future opportunities," said Probir Das, Chair and Managing Director of Terumo Asia Holdings, Regional Leader of Asia, Pacific & India and Executive Officer, Terumo Corporation.
IceCure has been approved by the Thai government to market the ProSense(TM) cryoablation system and related consumables for the destruction of benign and malignant tumors in the breast, lung, kidney, bone and additional indications.
About IceCure Medical
Founded in 2006, Israel-based IceCure Medical (TASE: ICCM), develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals. To learn more, please v isit: www.icecure-medical.com.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy t echnology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.
https://c212.net/c/img/favicon.png?sn=LN47744&sd=2020-10-05
View original content:http://www.prnewswire.com/news-releases/icecure-expands-strategic-collaboration-with-terumo-new-commercial-distribution-agreement-potentially-valued-at-over-7-0-million-301145529.html
More positive news!!! This little penny stock is growing. IMO this is a a hidden little-known "Diamond in the Rough". Time will tell.
SOURCE IceCure Medical
https://rt.prnewswire.com/rt.gif?NewsItemId=LN47744&Transmission_Id=202010050800PR_NEWS_USPR_____LN47744&DateId=20201005
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
Recent ICCM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 12:30:13 PM
- IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate • PR Newswire (US) • 09/24/2024 12:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 12:15:05 PM
- Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues • PR Newswire (US) • 09/16/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 12:10:20 PM
- IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 • PR Newswire (US) • 09/12/2024 12:00:00 PM
- IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences • PR Newswire (US) • 09/04/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/28/2024 12:45:02 PM
- USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/20/2024 01:03:39 PM
- IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets • PR Newswire (US) • 08/20/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 12:00:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 12:45:02 PM
- IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery • PR Newswire (US) • 08/14/2024 12:30:00 PM
- IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 • PR Newswire (US) • 08/13/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/07/2024 12:45:23 PM
- IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials" • PR Newswire (US) • 08/07/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/06/2024 08:35:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/22/2024 01:00:49 PM
- 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society • PR Newswire (US) • 07/22/2024 12:30:00 PM
- IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 07/19/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/16/2024 08:35:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/09/2024 12:45:14 PM
- European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer • PR Newswire (US) • 07/09/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes • PR Newswire (US) • 07/01/2024 12:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM